1. Diabetes and Fatty Liver.
- Author
-
Stefan N and Roden M
- Subjects
- Germany epidemiology, Greece epidemiology, Humans, Prevalence, Diabetes Complications epidemiology, Diabetes Complications metabolism, Diabetes Complications therapy, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 metabolism, Diabetes Mellitus, Type 2 therapy, Non-alcoholic Fatty Liver Disease epidemiology, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease therapy
- Abstract
Competing Interests: N. S. has participated in Scientific Advisory Boards of Gilead, Genkyotex, AstraZeneca, Boehringer Ingelheim, Sanofi, and clinical trials of AstraZeneca, Boehringer Ingelheim, Sanofi, DSM Nutritional Products and Roche Diagnostics. M. R. has participated on Scientific Advisory Boards of BMS, Boehringer Ingelheim Pharma, Eli Lilly, Fishawack Group, Gilead Sci., Novo Nordisk, Poxel S.A. Sociéte, Prosciento Inc., Sanofi, Servier Lab., Target Pharmasolutions, Terra Firma and in clinical trials of Astra Zeneca, Boehringer Ingelheim, Nutricia/Danone and Novartis.This is a translation of the DDG clinical practice guideline published in:Diabetologie 2019; 14 (Suppl 2): S222–S225.
- Published
- 2019
- Full Text
- View/download PDF